Skip to main content

Table 3 Comparison of liver function, renal function and blood routine before and after treatment in each group group

From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

  

Before treatment

Post Treatment

t-test(p-value)

TACE + Sunitinib group

Bilirubin(µmol/L)

12.3 ± 2.6

16.1 ± 4.8

< 0.001

Albumin(g/L)

37.62 ± 2.42

35.76 ± 5.41

0.091

BUN(mmol/L)

6.34 ± 1.43

7.71 ± 0.89

< 0.001

Cr(µmol/L)

87.4 ± 21.1

110.3 ± 20.8

< 0.001

GFR(ml/min)

107.06 ± 8.29

95.78 ± 12.97

< 0.001

WBC(G/L)

4.43 ± 0.72

6.92 ± 0.72

< 0.001

RBC(T/L)

4.39 ± 0.44

3.64 ± 0.66

< 0.001

PLT(G/L)

128.81 ± 19.93

95.40 ± 18.03

< 0.001

Sunitinib group

Bilirubin(µmol/L)

11.4 ± 3.0

15.0 ± 5.3

< 0.001

Albumin(g/L)

38.42 ± 3.37

33.37 ± 3.05

< 0.001

BUN(mmol/L)

6.07 ± 1.41

7.54 ± 0.98

< 0.001

Cr(µmol/L)

89.4 ± 17.7

105.0 ± 25.6

< 0.001

GFR(ml/min)

104.58 ± 8.81

99.34 ± 12.46

0.023

WBC(G/L)

4.63 ± 0.62

3.52 ± 0.73

< 0.001

RBC(T/L)

4.53 ± 0.58

3.37 ± 0.74

< 0.001

PLT(G/L)

124.67 ± 20.31

87.90 ± 23.32

< 0.001